Bio-Techne (TECH) Receivables (2010 - 2026)
Bio-Techne (TECH) posted quarterly Receivables of $214.6 million for Q1 2026, down 9.52% year-over-year from $237.1 million in Q1 2025, and up 16.22% quarter-over-quarter from $184.6 million in Q4 2025.
Bio-Techne (TECH) Receivables (2010 - 2026) Analysis & Trends
Bio-Techne's Receivables history runs 17 years deep, the most recent figure standing at $214.6 million for Q1 2026.
- In Q1 2026, Receivables fell 9.52% year-over-year to $214.6 million; the TTM figure through Mar 2026 stood at $214.6 million (down 9.52% YoY), while the FY2025 annual figure was $206.9 million, down 14.3% from the prior year.
- Receivables for Q1 2026 stood at $214.6 million, up from $184.6 million in the prior quarter.
- The five-year high for Receivables was $241.4 million in Q2 2024, with the low at $174.2 million in Q3 2022.
- The 5-year median for Receivables is $207.5 million (2023), against an average of $208.3 million.
- The sharpest annual moves came in 2022 and 2025: Receivables surged 33.82% in 2022, then slipped 17.79% in 2025.
- Bio-Techne's Receivables stood at $184.8 million in 2022, then rose by 12.28% to $207.5 million in 2023, then advanced by 5.06% to $217.9 million in 2024, then slipped by 15.29% to $184.6 million in 2025, then increased by 16.22% to $214.6 million in 2026.
- Business Quant data shows TECH's Receivables at $214.6 million in Q1 2026, $184.6 million in Q4 2025, and $183.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Bio-Techne | 11.33 Bn | 11.12 Bn | 208.29 Mn | 214.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 214.56 Mn |
| Dec 31, 2025 | 184.61 Mn |
| Sep 30, 2025 | 183.90 Mn |
| Jun 30, 2025 | 206.88 Mn |
| Mar 31, 2025 | 237.14 Mn |
| Dec 31, 2024 | 217.94 Mn |
| Sep 30, 2024 | 223.69 Mn |
| Jun 30, 2024 | 241.39 Mn |
| Mar 31, 2024 | 227.89 Mn |
| Dec 31, 2023 | 207.45 Mn |
| Sep 30, 2023 | 204.57 Mn |
| Jun 30, 2023 | 218.47 Mn |
| Mar 31, 2023 | 216.42 Mn |
| Dec 31, 2022 | 184.76 Mn |
| Sep 30, 2022 | 174.17 Mn |
| Jun 30, 2022 | 194.55 Mn |
| Mar 31, 2022 | 202.10 Mn |
| Dec 31, 2021 | 152.90 Mn |
| Sep 30, 2021 | 147.55 Mn |
| Jun 30, 2021 | 145.39 Mn |